Subscribe to Search results

Ministers continued to stress the need for collaboration between Scotland and England in manufacturing blood products.

Published on:

A NBTS meeting was held when it became apparent that any further plasma provided to BPL for fractionation would have to be dealt with in "unsatisfactory accommodation".

Published on:

R Smart published a report titled "Blood Products Laboratory: Redevelopment".

Published on:

At a meeting of the Scientific and Technical Committee for the Central Blood Laboratories, members did not support commercial development, and recommended that no time should be lost in planning for a completely new NHS plant.

Published on:

Ministers decided to defer the eventual decision on whether to build a new laboratory within the NHS until other possibilities had been investigated.

Published on:

Dr Lane was authorised to proceed with the stop-gap project. The DHSS anticipated that the sum of £750,000 would be available for the capital development of BPL in 1980/1981.

Published on:

It was not until this time that Dr Lane was given formal authority to proceed to tender with MARP01, the name given to the stop-gap proposal.

Published on:

Dr Gunson tabled a paper concluding that the number of plasmapheresis facilities should be increased. The Advisory Committee of the NBTS agreed to set up a Working Party and liaise with Scotland.

Published on:

The Working Party to Advise on Plasma Supplies for Self-Sufficiency in Blood Products published a preliminary report estimating costs of plasmapheresis compared favourably with the estimated cost of obtaining the same weight of whole blood.

Published on:

A Policy Steering Group for the Redevelopment of BPL meeting was held.

Published on:

Angus MacPherson wrote a letter to John Harley discussing the results of the shift working trial and outlining that the necessary building works could be completed in approximately two and a half years.

Published on:

Planning was eventually under way for a new building to constitute BPL at Elstree.

Published on:

A meeting of regional transfusion directors was held at BPL to receive information concerning the future requirements for increased supply of plasma for fractionation.

Published on:

A report was published titled "Value of SAG-M Systems in the Provision of Plasma Products".

Published on:

BPL noted that for the first year since Hepatitis B testing had first been carried out none of the five-litre plasma pools screened for Hepatitis B at regional transfusion centres and dispatched to the BPL had tested positive for Hepatitis B.

Published on:

Plasmapheresis grew as a source of plasma and, by 1986/1987, had given rise to just over 10% of the plasma sent to BPL.

Published on:

A new scheme of distribution for NHS Factor 8 concentrates was introduced. The amount to be sent to each region would be calculated by reference to the number of patients who had been reported as being treated in the haemophilia centres of that region in 1974.

Published on:

SAG-M was most likely introduced in September 1982.

Published on:

In Parliament, Dr Owen described the Government's policy as making the NHS self-sufficient in the production of Factor 8 as soon as "practicable".

Published on:

Elstree and Oxford were producing around 15 million international units of Factor 8 and NBTS was producing about the same amount in terms of cryoprecipitate.

Published on: